Retatrutide vs Mounjaro
Retatrutide vs Mounjaro – 5 Key Differences Every UK Researcher Should Know
Understanding the Retatrutide vs Mounjaro Comparison
The retatrutide vs mounjaro comparison has become one of the most searched topics among researchers and healthcare professionals investigating next-generation weight management compounds. Both medications are manufactured by Eli Lilly and target the incretin hormone system, but they differ fundamentally in their receptor activity and approval status. Understanding the retatrutide vs mounjaro differences is essential for researchers evaluating the current landscape of GLP-1 based therapies.
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, while Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist that has received MHRA approval for both type 2 diabetes and weight management in the UK. This fundamental mechanistic difference shapes every aspect of the retatrutide vs mounjaro comparison, from clinical efficacy to side effect profiles.
For researchers seeking high-purity retatrutide for laboratory applications, our Retatrutide product page provides research-grade material with complete analytical documentation. Similarly, our Tirzepatide product page offers research-grade Mounjaro analogue for comparative studies.
Mechanism of Action: Retatrutide vs Mounjaro Receptor Activity
How Retatrutide Works
Retatrutide is a triple hormone receptor agonist that binds to and activates three distinct receptors: GLP-1, GIP, and glucagon (GCG). This triple mechanism distinguishes retatrutide from all currently approved weight management medications. The addition of glucagon receptor activity increases energy expenditure, meaning the compound theoretically promotes weight loss through two complementary mechanisms: appetite suppression and enhanced caloric burn.
According to research published in BMJ Medicine, next-generation incretin-based treatments including retatrutide achieve greater weight loss than conventional GLP-1 receptor agonists. The glucagon component is believed to contribute to this enhanced efficacy by increasing resting energy expenditure.
How Mounjaro Works
Mounjaro (tirzepatide) is a dual agonist targeting only GLP-1 and GIP receptors. This dual mechanism produces significant appetite suppression and improved glycemic control, but does not include the glucagon-mediated energy expenditure effects seen with retatrutide. Tirzepatide has been extensively studied in the SURMOUNT and SURPASS clinical trial programmes, establishing its efficacy and safety profile across multiple patient populations.
Key Mechanistic Differences in Retatrutide vs Mounjaro
| Feature | Retatrutide | Mounjaro (Tirzepatide) |
|---|---|---|
| Receptor Targets | GLP-1, GIP, Glucagon | GLP-1, GIP |
| Energy Expenditure Effect | Yes (via glucagon) | Minimal |
| Approval Status | Investigational | MHRA Approved |
| UK Availability | Clinical trials only | Prescription available |
Clinical Trial Efficacy: Retatrutide vs Mounjaro Results
Retatrutide Clinical Data
Retatrutide has demonstrated remarkable weight loss efficacy in clinical trials. Phase 2 data showed that participants receiving the highest 12mg dose lost an average of 24.2% of their starting body weight over 48 weeks. Phase 3 trial data presented in 2026 showed even more impressive results: participants lost an average of 28.3% of their initial body weight over 80 weeks.
A network meta-analysis published in Wiley Online Library found that retatrutide and dual agonists achieved equivalent mean weight loss of −11.0 kg, surpassing GLP-1 receptor agonists at −9.0 kg, with retatrutide excelling at achieving ≥15% weight loss (OR 54.6). The analysis concluded that retatrutide offers superior weight loss efficacy but with a higher adverse event risk.
Mounjaro Clinical Data
Mounjaro has established a strong efficacy profile through its clinical development programme. The SURMOUNT-1 trial demonstrated up to 22.5% mean body weight reduction over 72 weeks at the 15mg dose in adults without type 2 diabetes. Real-world data from the SHAPE study has confirmed that tirzepatide consistently outperforms semaglutide in patients without type 2 diabetes.
A systematic review published by The BMJ compared obesity drugs and found that tirzepatide led with −14.9% weight loss at one year versus lifestyle modification.
Efficacy Comparison Summary for Retatrutide vs Mounjaro
Based on available clinical trial data, the retatrutide vs mounjaro efficacy comparison favours retatrutide for average weight loss, though direct head-to-head trials comparing the two compounds have not yet been conducted. Researchers should note that Phase 2 results do not always translate directly to Phase 3 outcomes, and long-term safety data for retatrutide remains limited compared to tirzepatide.
Retatrutide Price Per Month and Cost Considerations
The retatrutide price per month is a complex topic because the compound is not yet approved for commercial sale. Understanding the current pricing landscape is essential for researchers and healthcare professionals planning budgets or advising patients. When considering the retatrutide vs mounjaro cost comparison, Mounjaro currently has the advantage of established UK pricing.
Current Retatrutide Pricing
As of 2026, there is no approved retail price for retatrutide because it remains an investigational compound. The only legitimate access routes are clinical trial enrolment (free) or compounded products from licensed pharmacies, which are advertised at approximately $300 to $600 per month but are not FDA approved.
Research peptide suppliers offer retatrutide at varying prices, with a 10mg vial typically ranging from $120 to $200 depending on the supplier. However, the retatrutide price per month depends entirely on the weekly dose used. At a starting dose of 2mg weekly, a 10mg vial may last approximately five weeks, bringing the monthly cost to approximately $120-$200. At a maintenance dose of 8-12mg weekly, monthly costs could reach $480-$1,200.
Projected Brand Pricing
When retatrutide receives regulatory approval, its price is expected to anchor to Eli Lilly’s existing GLP-1 lineup rather than the research market. Tirzepatide, sold as Zepbound for weight loss, carries a list price near $1,060 per month before discounts. Projections suggest retatrutide could launch at $1,000-$1,300 per month before insurance, with manufacturer savings cards potentially reducing costs to $550-$700.
Mounjaro UK Pricing
For comparison, Mounjaro is available in the UK through private prescriptions at approximately £150 to £220 per monthly pen depending on the dose. The NHS reimbursement price was redetermined in September 2025, with prices ranging from £133 for the 2.5mg dose to £330 for the 15mg dose according to the NHSBSA.
| Dose | Mounjaro UK Private Price | NHS Reimbursement Price |
|---|---|---|
| 2.5mg | £149–£165 | £133 |
| 7.5mg | £175–£195 | £255 |
| 12.5mg | £195–£215 | £330 |
Side Effects: Retatrutide vs Mounjaro Tolerability
Shared Gastrointestinal Effects
Both retatrutide and Mounjaro share a similar baseline of gastrointestinal side effects because both medications slow gastric emptying. The most commonly reported side effects include nausea, vomiting, diarrhoea, constipation, decreased appetite, acid reflux, fatigue, and headaches. These effects typically peak when treatment starts or during dose escalation and improve as the body adjusts.
Retatrutide-Specific Side Effects
Because retatrutide targets glucagon in addition to GLP-1 and GIP, it introduces side effects not typically seen with Mounjaro. According to clinical trial data, retatrutide has been associated with a more noticeable increase in resting heart rate, averaging 6.7 to 7 beats per minute compared to Mounjaro’s 2.1 to 5.4 beats per minute increase. Trials also noted transient, non-serious irregular heartbeats or palpitations in 2% to 11% of patients depending on dose.
A unique side effect called dysesthesia has emerged in retatrutide clinical trials, affecting approximately 21% of patients on the highest dose. Patients describe this as an altered sense of touch where skin feels abnormally sensitive, burning, tingling, or tender against clothing or water.
Discontinuation Rates in Retatrutide vs Mounjaro Trials
The Bayesian network meta-analysis published in Wiley Online Library found that retatrutide had the highest adverse event risk among the compounds analysed. A separate analysis published by BMJ Medicine noted that newer treatments producing greater weight loss were not necessarily better tolerated, with low-certainty evidence suggesting higher rates of treatment discontinuation due to adverse events with retatrutide.
Regulatory Status and UK Availability
Retatrutide Approval Timeline
Retatrutide remains an investigational compound as of September 2026. Eli Lilly has reported that it plans to submit an application to the FDA in the first quarter of 2027. UK availability is realistically expected in 2027 at the earliest, likely later, following FDA, EMA, and MHRA review processes.
The MHRA has issued a stark warning about retatrutide, stating it “has not been authorised for use in the UK, meaning anyone selling this product is doing so illegally.” The agency emphasised that these products “haven’t been tested for safety, quality or effectiveness and there’s no guarantee that they even contain retatrutide.”
Eli Lilly has taken aggressive legal action against illegal sales of retatrutide, filing six lawsuits against online peptide sellers, medical spas, and other companies accused of offering products labeled as retatrutide despite the drug remaining unapproved. The MHRA has also disrupted multiple illegal manufacturing facilities, including raids in Lincolnshire and Nottinghamshire that seized almost 2,000 doses of unauthorised weight loss medicines including retatrutide.
Mounjaro UK Availability
Mounjaro is fully approved by the MHRA and widely available for both type 2 diabetes and weight management in the UK. It received NICE technology appraisal approval (TA1026) for weight management in England, though NHS access comes with strict eligibility criteria including a BMI threshold and qualifying comorbidities.
NHS spending on tirzepatide reached £574 million in 2025-26, an almost fivefold annual increase, making it the highest annual spend on a single medicine. The phased rollout is based on clinical need over a 12-year period to manage affordability concerns.
Frequently Asked Questions
What is the main difference between retatrutide and Mounjaro?
The primary retatrutide vs mounjaro difference is receptor targeting. Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors, while Mounjaro (tirzepatide) is a dual agonist targeting only GLP-1 and GIP. The additional glucagon activity in retatrutide increases energy expenditure, potentially leading to greater weight loss.
Which is more effective for weight loss, retatrutide or Mounjaro?
Based on clinical trial data, the retatrutide vs mounjaro efficacy comparison favours retatrutide. Phase 3 data showed approximately 28% weight loss at 80 weeks for retatrutide, compared to 22.5% at 72 weeks for Mounjaro’s highest dose. However, direct head-to-head trials have not been conducted.
What is the retatrutide price per month?
There is no approved retail price for retatrutide because it remains investigational. Compounded products are advertised at $300-$600 per month, while research peptide suppliers offer 10mg vials at $120-$200 depending on supplier. Projected brand pricing after approval is $1,000-$1,300 per month before insurance.
Is retatrutide available in the UK?
No. Retatrutide is not available in the UK outside of clinical trials. It has not been approved by the MHRA, and UK availability is realistically expected in 2027 at the earliest. Mounjaro is the only one of these two medications that combines strong efficacy data with full UK licensing.
Can I buy retatrutide online for research?
Cocer Peptides supplies research-grade retatrutide for laboratory applications only. All products are intended strictly for in-vitro research and are not for human consumption. For comparative studies, we also offer research-grade tirzepatide.
Conclusion
The retatrutide vs mounjaro comparison reveals two compounds at very different stages of development. Retatrutide represents the next generation of incretin-based therapies, offering potentially superior weight loss efficacy through its triple agonist mechanism, but with limited safety data and no current regulatory approval. Mounjaro represents the current standard, with extensive clinical data, full MHRA approval, and established UK availability. For any researcher weighing the retatrutide vs mounjaro decision for comparative studies, both compounds are available as research-grade material.
For researchers investigating these compounds, Cocer Peptides provides high-purity retatrutide and tirzepatide for laboratory applications. Visit our About Us page to learn more about our research-grade standards.
Ready to Advance Your Research?
View Retatrutide Product Page | View Tirzepatide Product Page | Contact Our Research Team